You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy ORLANDO, Fla., May 30, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that...
Deerfield, IL (May 28, 2009) – The Food and Drug Administration (FDA) has granted Astellas Pharma US, Inc. approval for the use of Prograf® (tacrolimus) in conjunction with mycophenolate...
DEERFIELD, IL, May 28, 2009 – Astellas Pharma US, Inc. (“Astellas”) recently hired Walt Johnston as vice president of marketing. Reporting directly to Patrick Shea, senior vice president of...
Read more about Astellas Announces New Vice President of Marketing
Data Showed Tarceva Improved PFS in Patients with Both Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma Patients with an EGFR Mutation Achieved a 10 Fold Increase in the Time Patients Live...
Arginine vasopressin (AVP) receptor antagonist now available in new premixed formulation DEERFIELD, Illinois, April 1, 2009 — Astellas Pharma US, Inc. today announced the commercial availability...
Follow U.S. news
